Trial Profile
Randomised, open label study of rituximab/ibrutinib vs rituximab/chemotherapy in older patients with untreated mantle cell lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Rituximab; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms ENRICH
- 02 Dec 2022 This trial has been completed in England, according to ISRCTN record.
- 01 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 07 Jan 2021 Status changed from active, no longer recruiting to recruiting.